2025 Updates in Hematology and Oncology, Fresno

Fresno, CA US
July 26, 2025

This CME-accredited oncology conference, 2025 Updates in Hematology and Oncology, Fresno, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

ORGANIZING COMMITTEE

Conference Director: 

  • Binay Shah, MD, MHA - Binaytara

Conference Co- Chairs:

  • Sanjay Hinduja, MD - UCSF Fresno
  • Haifaa Abdulhaq, MD - UCSF Fresno

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review common molecular abnormalities in various cancers and the optimal timing to test for these abnormalities.
  • Interpret the findings from next-generation sequencing and other biomarkers that indicate the likelihood of response to specific therapies while also understanding the inherent challenges.
  • Apply optimal strategies centered on molecular-targeted treatments in the management of patients with cancer.
  • Summarize emerging research, the mechanism of action, and the significance of new molecular-targeted treatments in managing cancer patients.
Course summary
Available credit: 
  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 ACPE Pharmacy

    The Binaytara is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-023-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 6.50 AMA PRA Category 1 Credit™

    The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.
Course opens: 
04/11/2025
Course expires: 
10/26/2025
Event starts: 
07/26/2025 - 8:00am PDT
Event ends: 
07/26/2025 - 4:30pm PDT
Cost:
$350.00

Saturday, July 26th, 2025

All times are listed in Pacific Standard Time (PST)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:15 AM  Binaytara's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:15 AM – 09:30 AM  Session 1 - Hematologic Malignancies

Session Chairs: Mohammed Bukari, MD, FACP

08:15 AM – 08:35 AM  MDS / Acute Leukemia - Tamer Othman, MD

08:35 AM – 08:55 AM  Lymphoma / CLL - Haifaa Abdulhaq, MD

08:55 AM – 09:15 AM  Multiple Myeloma - Swathi Namburi, MD

09:15 AM – 09:30 AM  Q & A


09:30 AM – 10:15 AM  Break & Exhibits


10:15 AM – 11:15 AM  Session 2 - Changing Landscapes in Oncology: Liquid Biopsy / Cellular Therapy

Session Chairs: Matthew Gubens, MD, MS, FASCO

10:15 AM – 10:35 AM  Liquid Biopsy / ctDNA in Clinical Practice - Matthew Gubens, MD, MS, FASCO

10:35 AM – 10:55 AM  Cellular Therapy - Madhav Seshadri, MD

10:55 AM – 11:15 AM  Case-Based Discussion - Omar Mahmood, MD


11:15 AM – 12:15 PM  Session 3 - Thoracic Oncology

Session Chairs: Sanjay Hinduja, MD

11:15 AM – 11:35 AM  Early-Stage Lung Cancer - Deepti Behl, MD

11:35 AM – 11:55 AM  Advanced Lung Cancer - Matthew Gubens, MD, MS, FASCO

11:55 AM – 12:15 PM  Case-Based Discussion - Cathy Zhang, MD


12:15 PM – 01:15 PM  Lunch & Exhibits

12:15 PM – 01:00 PM  Product Theater Sponsored by Menarini Stemline

Title: ORSERDU for patients with ER+/HER2- ESR1- mutated mBC, upon progression on 1L ET + CDK4/6i

*This is a non-CME accredited activity*


01:15 PM – 02:30 PM  Session 4 - General Oncology

Session Chair: Varun Monga, MD, MBBS

01:15 PM – 01:35 PM  GU Oncology - Sandy Srinivas, MD

01:35 PM – 01:55 PM  Sarcoma - Varun Monga, MD, MBBS

01:55 PM – 02:15 PM  Cutaneous Malignancies - Adil Daud, MD

02:15 PM – 02:30 PM  Q & A


02:30 PM – 02:45 PM  Break & Exhibits


02:45 PM – 03:45 PM  Session 5 - Breast Cancer

Session Chair: Li Lisa Ge, MD

02:45 PM – 03:05 PM  Early-Stage Breast Cancer - Hemali Batra-Sharma, MD

03:05 PM – 03:25 PM  Metastatic Breast Cancer - Pamela Munster, MD

03:25 PM – 03:45 PM  Panel Discussion - Chase Atiga, MD


03:45 PM – 04:45 PM  Session 6 - GI Cancer

Session Chair: Jun Gong, MD

03:45 PM – 04:05 PM  Upper GI Malignancies - Ronan Hsieh, MD

04:05 PM – 04:25 PM  Lower GI Malignancies - Jun Gong, MD

04:25 PM – 04:45 PM  Panel Discussion - Tanjot Saini, MD


04:45 PM  Adjourn

 

DoubleTree by Hilton Hotel Fresno Convention Center
2233 Cesar Chavez Blvd
Fresno, CA 93721
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Financial Support) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Abbvie;.

Sanjay Hinduja

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Mohammed BUKARI

has no relevant financial relationships to disclose at this time.

Li Ge, MD

has no relevant financial relationships to disclose at this time.

Jun Gong, MD

has a financial relationship (Professional Services) with Taiho;.

Varun Monga

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Hemali Batra-Sharma, MD

has a financial relationship (Other) with Doximity;.
has a financial relationship (Other) with Curio Science;.
has a financial relationship (Other) with MJH Life Sciences (Targeted Oncology, OncLive);.
has a financial relationship (Stock) with Tempus;.
has a financial relationship (Travel) with Jazz Pharmaceuticals;.

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with janssen;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.

Jun Gong, MD

has a financial relationship (Professional Services) with Taiho;.

Matthew Gubens

has a financial relationship (Independent contractor) with Johnson and Johnson;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with Atreca;.
has a financial relationship (Independent contractor) with OncoHost;.
has a financial relationship (Independent contractor) with Invitae;.
has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with Bicycle;.
has a financial relationship (Independent contractor) with Catalyst;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Nuvalent;.
has a financial relationship (Independent contractor) with Natera;.

Ronan Hsieh, MD, MS

has a financial relationship (Financial Support) with Curio Science;.
has a financial relationship (Travel) with Merck;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Travel) with Medscape;.

Varun Monga

has no relevant financial relationships to disclose at this time.

Pamela Munster

has a financial relationship (Grant Or Contract) with Clovis;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Grant Or Contract) with Blueprint;.
has a financial relationship (Grant Or Contract) with Scorpion;.
has a financial relationship (Grant Or Contract) with Relay;.
has a financial relationship (Independent contractor) with Merck ;.
has a financial relationship (Grant Or Contract) with InventisBIo;.
has a financial relationship (Grant Or Contract) with Revolution;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with ABBVIE;.
has a financial relationship (Grant Or Contract) with Merck;.

Swathi Namburi, MD

has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with Targeted Oncology;.
has a financial relationship (Other) with Pfizer;.

Tamer Othman

has no relevant financial relationships to disclose at this time.

Madhav Seshadri, MD

has a financial relationship (Grant Or Contract) with Cabaletta Bio;.
has a financial relationship (Grant Or Contract) with Kyverna Therapeutics;.
has a financial relationship (Grant Or Contract) with BeOne Therapeutics;.
has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Abbvie;.

Sandy Srinivas, MBBS

has a financial relationship (Professional Services) with merck;.
has a financial relationship (Professional Services) with novartis;.
has a financial relationship (Professional Services) with jansen;.
Case Presenter(s)

Chase Atiga, MD

has no relevant financial relationships to disclose at this time.

Omar Mahmood, M.D.

has no relevant financial relationships to disclose at this time.

Tanjot Saini, MD

has no relevant financial relationships to disclose at this time.

Cathy Zhang, M.D.

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 ACPE Pharmacy

    The Binaytara is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-023-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 6.50 AMA PRA Category 1 Credit™

    The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://www.sponsorships.binaytara.org/FresnoHemeOnc

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.